What happened with SMTI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Sanara MedTech supplies products that surgeons use to manage wounds, repair soft tissue and support bone fusion, primarily in the United States. Hospitals and surgical centers buy the products, usually through orders shipped directly by the company. Soft tissue repair supplies account for most revenue, with CellerateRX Surgical generating the substantial majority of product sales. This collagen powder helps surgeons manage surgical wounds. Other offerings include BIASURGE, a sterile wound-irrigation solution, and bone fusion products.
The business depends on surgeons adopting its products and on outside manufacturers supplying them. Sanara buys its principal revenue-producing products from a single manufacturer and licenses most of the products it sells. Continued sales therefore depend on product supply and maintaining those licenses. It also relies on development partners to obtain required FDA authorizations, and it may promote products only for uses allowed by their labeling.
Sanara now focuses exclusively on surgical products and technologies. It discontinued Tissue Health Plus (THP), its post-acute wound-care services initiative, in September 2025.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Integra LifeSciences competes with Sanara for hospitals’ and surgical centers’ spending on products that repair tissue during surgery. Its Tissue Technologies business is the part to watch for competition with Sanara’s surgical biomaterials, rather than its larger neurosurgery business.
Solventum’s wound-care products and synthetic tissue matrices compete with the surgical wound-management and tissue-repair products Sanara sells to hospitals and surgical centers. Watch those products within Solventum’s MedSurg business, rather than its dental products or healthcare software, for developments relevant to Sanara.
Smith & Nephew competes with Sanara through advanced wound-management products and surgical repair technologies that overlap with Sanara’s tissue-repair offerings to hospitals and surgical centers.
BD competes with Sanara to supply healthcare institutions with products for rinsing surgical wounds and biomaterials for tissue repair. News about those surgical products is more relevant to Sanara’s BIASURGE irrigation solution and tissue-repair range than BD’s laboratory or diagnostic products.
Medline competes with Sanara for hospital and surgery-center purchases of surgical wound-irrigation products and tissue-repair biomaterials. Medline also supplies a broad range of medical-surgical goods and supply-chain services, so focus on its wound-irrigation and biomaterial offerings when assessing competition for Sanara.
Zimmer Biomet’s orthopedic biologics compete with Sanara’s bone-fusion products for use by orthopedic surgeons treating hospital and surgical-center patients. Watch its biologics product developments for competition with Sanara’s BiFORM implant and ALLOCYTE Plus donor-bone matrix, rather than treating its whole orthopedic portfolio as a direct rival.
CONMED and Sanara both depend on U.S. orthopedic and general surgery volumes: CONMED sells surgical devices to the hospitals and surgeons that buy Sanara’s wound-management products. Watch CONMED’s orthopedic and general surgery sales for clues to procedure-related demand for CellerateRX Surgical, which supplies the substantial majority of Sanara’s product sales revenue.
Integra LifeSciences Holdings earningsIART
Integra LifeSciences’ Tissue Technologies business competes with Sanara MedTech for hospitals’ and surgeons’ spending on surgical biomaterials, so its report can show whether that competition is intensifying.
Focus on Integra LifeSciences’ Tissue Technologies results and commentary on those products, not its neurosurgery business. Strength would suggest hospitals and surgeons are buying more surgical biomaterials, but also that Sanara MedTech faces stronger competition for soft-tissue repair sales. Weakness could mean less competitive pressure, but would not prove Sanara’s sales are growing.
CONMED Corporation earningsCNMD
CONMED’s orthopedic and general surgery sales offer a read on procedure-related demand, which also shapes purchases of Sanara MedTech’s CellerateRX Surgical.
See whether CONMED’s orthopedic and general surgery sales strengthen or weaken together. Strength in both would suggest procedure demand at hospitals and surgery centers is supportive of Sanara MedTech’s surgical wound-management products. Weakness in both would point to pressure on related purchases, but would not establish Sanara’s own sales result.
Zimmer Biomet Holdings, Inc. earningsZBH
Zimmer Biomet’s orthopedic biologics compete with Sanara MedTech’s bone-fusion products for related surgical uses, and its report can show how that competition is developing.
Focus on Zimmer Biomet’s orthopedic biologics results and product developments, not its entire orthopedic business. Strength or competitive product momentum could increase pressure on Sanara MedTech’s BiFORM and ALLOCYTE Plus; weakness could mean less pressure, but would not establish Sanara’s bone-fusion sales.
Sanara MedTech Inc. earningsThis company
Sanara MedTech relies mainly on soft-tissue repair products for sales, and this report will show whether product growth is still outpacing selling and research costs.
Read sales of soft-tissue repair and bone-fusion products alongside selling and research costs. If product sales grow faster, expansion among hospitals and surgery centers is bringing in revenue faster than it adds costs. If sales slow while costs keep rising, growth is doing less to improve operations and the business remains more reliant on cash and financing.
